Lunesta and Rebound effect - a phase IV clinical study of FDA data

Summary:

Rebound effect is reported as a side effect among people who take Lunesta (eszopiclone), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Rozerem, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Rebound effect when taking Lunesta. It is created by eHealthMe based on reports of 25,141 people who have side effects when taking Lunesta from the FDA, and is updated regularly.

What is Lunesta?

Lunesta has active ingredients of eszopiclone. It is often used in insomnia. eHealthMe is studying from 26,936 Lunesta users. Check the latest studies of Lunesta.

What is Rebound effect?

Rebound effect (take-back effect) is found to be associated with 368 drugs and 569 conditions by eHealthMe. Check the latest studies of Rebound effect.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

25,141 people reported to have side effects when taking Lunesta.
Among them, 39 people (0.16%) have Rebound effect.

Among these 39 people:

How long have people been on Lunesta when they have Rebound effect? *

What is the gender of people who have Rebound effect when taking Lunesta? *

female: 65.79 %
male: 34.21 %

What is the age of people who have Rebound effect when taking Lunesta? *

What are other drugs people take besides Lunesta? *

What are other side effects people have besides Rebound effect? *

Taste - Impaired: 7 people, 17.95%
Drug Ineffective: 6 people, 15.38%
Muscle Spasms (muscle contraction): 4 people, 10.26%
Memory Loss: 3 people, 7.69%
Left Ventricular Hypertrophy (the thickening of the myocardium (muscle) of the left ventricle of the heart): 3 people, 7.69%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 7.69%
Confusional State: 3 people, 7.69%
Sleep Apnea Syndrome: 3 people, 7.69%
Depression: 3 people, 7.69%
High Blood Pressure: 3 people, 7.69%

What are the existing conditions these people have? *

Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder): 2 people, 5.13%
Pain: 2 people, 5.13%
Osteoporosis Post-Menopausal (weak bone with possibility to break after stopped menstrual cycles): 2 people, 5.13%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 5.13%
High Blood Pressure: 1 person, 2.56%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 2.56%
Depression: 1 person, 2.56%
Facial Pain: 1 person, 2.56%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 2.56%
Headache (pain in head): 1 person, 2.56%

* Approximation only. Some reports may have incomplete information.

Do you take Lunesta and have Rebound effect?

- Check whether Rebound effect is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lunesta:

Lunesta (26,936 reports)

Rebound effect treatments and more:

Rebound effect (8,859 reports)

Browse all side effects of Lunesta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rebound effect:

Rebound effect (368 drugs)

Browse all the conditions that are associated with Rebound effect:

Rebound effect (569 conditions)

Related publications that referenced our studies

Lai SW, Lai HC, Lin CL, Liao KF, "Zopiclone use associated with increased risk of acute pancreatitis: a case–control study in Taiwan", International journal of clinical practice, 2015 Nov .
Lai SW, Lai HC, Lin CL, Liao KF, "Zopiclone use associated with increased risk of acute pancreatitis: a case–control study in Taiwan", International journal of clinical practice, 2015 Nov .

How the study uses the data?

The study uses data from the FDA. It is based on eszopiclone (the active ingredients of Lunesta) and Lunesta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.